Amgen Cash Flow Statement
NASDAQ: AMGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amgen free cash flow
In fiscal 2025, Amgen generated $9.96 billion of operating cash flow and spent $1.86 billion on capital expenditures. That left free cash flow of $8.10 billion, a free-cash-flow margin of 22.0% of revenue. Free cash flow was down 22.1% from the prior year's $10.39 billion.
Amgen returned $5.12 billion to shareholders through dividends, equal to 63% of free cash flow. Free cash flow covered dividend payments 1.6 times.
Summary generated from market data by MetaCap's automated system. Methodology
Amgen cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 7.71B | 4.09B | 6.72B | 6.55B | 5.89B | 7.26B | 7.84B | 8.39B | 1.98B | 7.72B |
| Net Income growth (YoY) | +88.53% | -39.11% | +2.52% | +11.18% | -18.87% | -7.37% | -6.58% | +324.15% | -74.37% | +11.28% |
| Depreciation & Amortization | 5.17B | 5.59B | 4.07B | 3.42B | 3.40B | 3.60B | 2.21B | 1.95B | 1.96B | 2.10B |
| Stock-Based Compensation | 494.00M | 530.00M | 431.00M | 401.00M | 341.00M | 330.00M | 308.00M | 311.00M | 329.00M | 311.00M |
| Change in Working Capital | -2.79B | 2.58B | -1.71B | -1.26B | -948.00M | 515.00M | 0 | 725.00M | 706.00M | -143.00M |
| Operating Cash Flow | 9.96B | 11.49B | 8.47B | 9.72B | 9.26B | 10.50B | 9.15B | 11.30B | 11.18B | 10.35B |
| Capital Expenditures | -1.86B | -1.10B | -1.11B | -936.00M | -880.00M | -608.00M | -618.00M | -738.00M | -664.00M | -738.00M |
| Investing Cash Flow | -1.94B | -1.05B | -26.20B | -6.04B | 733.00M | -5.40B | 5.71B | 14.34B | -4.02B | -8.66B |
| Dividends Paid | -5.12B | -4.83B | -4.56B | -4.20B | -4.01B | -3.75B | -3.51B | -3.51B | -3.37B | -3.00B |
| Share Repurchases | 0 | -200.00M | 0 | -6.36B | -4.97B | -3.49B | -7.70B | -17.79B | -3.16B | -2.96B |
| Debt Issued | 0 | 0 | 27.78B | 6.92B | 4.95B | 8.91B | 0 | 0 | 4.48B | 7.32B |
| Debt Repaid | -5.00B | -3.60B | -1.45B | 0 | -4.15B | -6.45B | -4.51B | -1.12B | -4.41B | -3.73B |
| Financing Cash Flow | -10.86B | -9.41B | 21.05B | -4.04B | -8.27B | -4.87B | -15.77B | -22.49B | -6.59B | -2.60B |
| Net Change in Cash | -2.84B | 1.03B | 3.31B | -360.00M | 1.72B | 229.00M | -908.00M | 3.15B | 559.00M | -903.00M |
| Free Cash Flow | 8.10B | 10.39B | 7.36B | 8.79B | 8.38B | 9.89B | 8.53B | 10.56B | 10.51B | 9.62B |
This table shows 10 annual periods of Amgen's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMGN's reporting calendar. What is a cash flow statement?